ExonHit Therapeutics is listed on the NYSE Alternext [ALEHT]. ExonHit is a fast emerging healthcare player active in both therapeutics and diagnostics. The Company is applying its proprietary technology, based on the analysis of alternative RNA splicing, to develop innovative molecular diagnostic tests and therapeutics for Alzheimer’s disease and cancer indications. ExonHit has a balanced investment strategy with internal development programs and strategic collaborations, in particular with bioMérieux and Allergan. ExonHit is headquartered in Paris, France and has U.S. offices in Gaithersburg, Maryland. Following the acquisition of In Gene Bioscience, the company changed it s name into Diaxonhit and became a fully integrated diagnostic company with products in infectious diseases, cancer and Alzheimer disease. Diaxonhit has two products in clinical phase in Alzheimer and pain.


Denis Lucquin

Denis Lucquin is a Managing Partner  of Sofinnova Partners. In life sciences, he specializes in industrial biotechnology investments. He joined Sofinnova in 1991. Denis began his career in academic research. For five years, he was in charge of the technology transfer department at the Institut Natio...